In Brief: Bayer BAY x1351
Executive Summary
Bayer BAY x1351: Preliminary analysis of data from Phase III trials of the anti-TNF monoclonal antibody does not show superiority to placebo in reducing mortality in septic shock patients. Bayer will await full analyses of the data, which it plans to present in late June and autumn to scientific meetings, before making a decision on continuing development. The company has invested in a $100 mil. biotechnology facility in Berkeley, Calif. to supply the product ("The Pink Sheet" April 14, T&G-5)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth